Late-life semaglutide treatment slows ageing and extends lifespan in female mice

TL;DR - A Nature study reports that three months of late-life semaglutide treatment improved physiological function, reduced ageing-associated hallmarks, and extended lifespan in female mice. The findings suggest potential geroprotective effects, but evidence provided is limited to a preclinical female-mouse study.

• Treatment was administered late in life for three months.
• Semaglutide attenuated multiple hallmarks of ageing.
• The intervention modulated nutrient-sensing pathways and conserved genetic regulators of ageing.
• Whether these effects generalize to male mice or humans is not established by the provided content.